Rimonabant, a Selective Cannabinoid CB1 Receptor Antagonist, Inhibits Atherosclerosis in LDL Receptor–Deficient Mice
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Objective— The objective of this study was to determine whether the potent selective cannabinoid receptor-1 antagonist rimonabant has antiatherosclerotic properties. Methods and Results— Rimonabant (50 mg/kg/d in the diet) significantly reduced food intake (from 3.35±.04 to 2.80±0.03 g/d), weight gain (from 14.6±0.7 g to −0.6±0.3 g), serum total cholesterol (from 8.39±0.54 to 5.32±0.18 g/L), and atherosclerotic lesion development in the aorta (from 1.7±0.22 to 0.21±0.037 mm 2 ) and aortic sinus (from 101 000±7800 to 27 000±2900 μm 2 ) of LDLR −/− mice fed a Western-type diet for 3 months. Rimonabant also reduced plasma levels of the proinflammatory cytokines MCP-1 and IL12 by 85% ( P <0.05) and 76% ( P <0.05), respectively. Pair-fed animals had reduced weight gain (6.2±0.6 g gain), but developed atherosclerotic lesions which were as large as those of untreated animals, showing that the antiatherosclerotic effect of rimonabant is not related to reduced food intake. Interestingly, rimonabant at a lower dose (30 mg/kg/d in the diet) reduced atherosclerosis development in the aortic sinus (from 121 000±20 000 to 62 000±11 000 μm 2 , 49% reduction, P <0.05), without affecting serum total cholesterol (7.8±0.7 g/L versus 8.1±1.3 g/L in the control group). Rimonabant decreased lipopolysaccharide (LPS)- and IL1β-induced proinflammatory gene expression in mouse peritoneal macrophages in vitro as well as thioglycollate-induced recruitment of macrophages in vivo (10 mg/kg, po bolus). Conclusions— These results show that rimonabant has antiatherosclerotic effects in LDLR −/− mice. These effects are partly unrelated to serum cholesterol modulation and could be related to an antiinflammatory effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maffei, M., Halaas, J., Ravussin, E., Pratley, R. E., Lee, G. H., Zhang, Y., Fei, H., Kim, S., Lallone, R., Ranganathan, S., et al. (1995) · Nature Medicine · doi:10.1038/nm1195-1155 · Cited by 3,725
Mechanisms linking obesity with cardiovascular disease
Van Gaal, L. F., Mertens, I. L., & De Block, C. E. (2006) · Nature · doi:10.1038/nature05487 · Cited by 2,814
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
Després, J.-P., Golay, A., & Sjöström, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044537 · Cited by 1,392
Activation of the peripheral endocannabinoid system in human obesity
Engeli, S., Böhnke, J., Feldpausch, M., Gorzelniak, K., Janke, J., Bátkai, S., Pacher, P., Harvey-White, J., Luft, F. C., Sharma, A. M., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.10.2838 · Cited by 686
Cited by
Macrophage death and defective inflammation resolution in atherosclerosis
Tabas, I. (2010) · Nature Reviews Immunology · doi:10.1038/nri2675 · Cited by 1,120
Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly
Pacher, P., Steffens, S., Haskó, G., Schindler, T. H., & Kunos, G. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.130 · Cited by 439
Is lipid signaling through cannabinoid 2 receptors part of a protective system?
Pacher, P., & Mechoulam, R. (2011) · Progress in Lipid Research · doi:10.1016/j.plipres.2011.01.001 · Cited by 414
Modulating the endocannabinoid system in human health and disease – successes and failures
Pacher, P., & Kunos, G. (2013) · The FEBS Journal · doi:10.1111/febs.12260 · Cited by 405
Bioactive lipids, inflammation and chronic diseases
Leuti, A., Fazio, D., Fava, M., Piccoli, A., Oddi, S., & Maccarrone, M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.028 · Cited by 358
Metadata
- Authors
- Dol-Gleizes, F., Paumelle, R., Visentin, V., Marés, A.-M., Desitter, P., Hennuyer, N., Gilde, A., Staels, B., Schaeffer, P., & Bono, F.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2009-01
- Volume
- 29
- Issue
- 1
- Pages
- 12-18
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2031828723
- Cited by
- 124
- References
- 5
- FWCI
- 7.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.